BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會


C4U Corporation


Company Info

Name /C4U Corporation

Address /Ascend Meguro 8F, 1-3-27 Shimo-Meguro, Meguro-ku, Tokyo Japan 153-0064

Website /


Name /Akimitsu Hirai

Title /President & CEO

Email /

Telephone /+81-90-4393-2810

Fax /

Mobile /

Company Type


About the Company

C4U is a privately held biotech company established in 2018. Our goal is to address unmet clinical needs by delivering safe and efficient gene therapies for genetic disorders though our proprietary NextGen CRISPR-Cas3 gene editing platform.

C4U owns an exclusive platform technology for the development of new gene therapies using CRISPR-Cas3 technology in the medical field, which is its primary focus area. We are seeking to strengthen our in-house pipelines with partnered projects and strategic alliances. We will also carry out joint research and technology licenses for applications in other fields benefiting from gene editing such as agriculture, fisheries, etc.

Brief Description of main products or services

Genome editing technology is receiving a lot of attention after CRISPR-Cas9 was awarded the Nobel Prize in 2020. Our proprietary NextGen CRISPR-Cas3 technology is different from Cas9 and has unprecedentedly higher target sequence specificity and higher efficiency. It is characterized by no off-target deletions (improved safety) and wider genome deletions (more efficient knockouts).

The entire CRISPR-Cas3 technology patent portfolio has been exclusively licensed by C4U from Osaka University. CRISPR-Cas3 patent landscape is totally independent from Cas9, and C4U can provide "Freedom to Operate".

In addition to its applications suitable for gene therapy, diagnostics, and bio-manufacturing, the CRISPR-Cas3 technology platform can also be applied to other fields, such as agriculture, fisheries, synthetic biology, and other industrial applications.

Contact Person

Name /Katsuyoshi Akiyama

Email /

Phone /+81-80-4651-3645